On the Risks of Phylogeny-Based Strain Prioritization for Drug Discovery: Streptomyces lunaelactis as a Case Study

On the Risks of Phylogeny-Based Strain Prioritization for Drug Discovery: Streptomyces lunaelactis as a Case Study

Strain prioritization for drug discovery aims at excluding redundant strains of a collection in order to limit the repetitive identification of the same molecules. In this work, we wanted to estimate what can be unexploited in terms of the amount, diversity, and novelty of compounds if the search is...

Full description

Bibliographic Details
Main Authors: Loïc Martinet, Aymeric Naômé, Dominique Baiwir, Edwin De Pauw, Gabriel Mazzucchelli, Sébastien Rigali
Format: Article
Language:English
Published: MDPI AG 2020-07-01
Series:Biomolecules
Subjects:
strain prioritization
metabolomics
chemical diversity
natural product
drug discovery
genome mining
Online Access:https://www.mdpi.com/2218-273X/10/7/1027

Internet

https://www.mdpi.com/2218-273X/10/7/1027

Similar Items